Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.
Yun-Yun XiongLiyuan WangYuesong PanMengxing WangLee H SchwammChunmiao DuanBruce C V CampbellShuya LiManjun HaoNa WuZhixin CaoShuangzhe WuZi-Xiao LiYong-Jun WangPublished in: Stroke and vascular neurology (2024)
The risk-benefit profile of tenecteplase thrombolysis was preserved in the elderly patients, which lends further support to intravenous 0.25 mg/kg tenecteplase as an alternative to alteplase in these patients.
Keyphrases
- acute ischemic stroke
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- pulmonary embolism
- high dose
- study protocol
- randomized controlled trial
- phase iii
- low dose
- intensive care unit
- respiratory failure
- patient reported outcomes
- drug induced
- phase ii
- aortic dissection
- mechanical ventilation